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Abstract
Although the clinical potential of bone mor-
phogenetic proteins (BMPs) has been known
for decades, their use in humans has only been
approved for a limited number of orthopaedic
conditions.  Promising  results  in  animals
demonstrate the utility of BMP-2 in regional
bone repair without using osteoconductors. To
our  knowledge,  no  comparable  human  case
has been described. We report the case of a 50-
year-old who suffered a femoral neck fracture.
After 9 months of extensive treatment, he was
still not pain-free. The following open-wedge
osteotomy  resulted  in  a  therapy-resistant
delayed union. We therefore conducted 4 com-
puter tomography-guided injections of recom-
binant human (rh) BMP-2 into the bone gap.
No osteoconductor was employed. Six weeks
later, there was a 55-60% defect filling. Follow-
up examination showed a complete union of
the bone defect. Our case report shows that in
a complicated delayed union rhBMP-2 can be
successfully  used  to  induce  bone  formation
without any osteoconductor. 
Introduction
Femoral neck fractures (FNF) belong to the
most frequent fractures in patients of all ages.
In younger patients (<55 years), internal fixa-
tion,  e.g.,  by  hip-screws,  is  preferred,  while
arthroplasty  is  commonly  used  in  older
patients (>70 years).1Although the vast major-
ity of human fractures show normal bone heal-
ing, approximately 5% per year do not heal and
are to be classified as delayed or non-unions.2,3
Delayed and non-unions constitute an obsta-
cle in the treatment of bone defects, since they
usually cause pain and possibly result in limb
length differences, potentially leading to avas-
cular necrosis and a severe loss of function.4
Intervention  is  therefore  inevitable:  although
surgery using internal or external fixation com-
bined with (autologous) bone-grafts is still con-
sidered the gold standard in the treatment of
non-unions, extracorporeal shock-wave therapy
(ESWT) and osteotomy are also said to result in
useful  outcomes.2-5 Trochanteric  open-wedge
osteotomy is invasive in nature and therefore
associated with the common operative risks. In
addition,  the  procedure  itself  can  foster
trochanteric  non-union.6 The  advantages  of
ESWT are its non-invasiveness and low rate of
complications.7 Results on its efficacy, however,
are  still  controversial.3-5 In  autologous  bone-
grafting, there is only a limited quantity of bone
available to harvest and the procedure is also
associated with significant complications, such
as persistent donor-site pain, local infection and
paresthesia.2
Recently,  bone  morphogenetic  proteins
(BMP) have become available to enhance bone
repair. BMP-2 and BMP-7 are supposed to have
the greatest osteoinductive capacity both in ani-
mal  and  in  human  trials.  However,  little  is
known about long-term effects, and to date, the
use of BMPs in humans has only been approved
for  the  treatment  of  a  limited  number  of
orthopaedic conditions;2,8,9 the benefits of BMPs
in  the  treatment  of  delayed  and  non-unions
remain  unclear.10,11 One  of  the  clinical  chal-
lenges in the use of BMPs is to transport the
growth factors to the bone repair-site and to
maintain  a  sustained,  therapeutic  concentra-
tion at repair-site, high enough to evoke an ade-
quate osteoinductive reaction.1,2 In animal tri-
als, there have been first successful attempts to
enhance fracture repair by regional use of BMP-
2 without the use of traditional osteoconduc-
tors: Baltzer et al.12 injected adenoviral vectors
encoding for BMP-2 into the segmental defect-
site in femora of rabbits. Schmidmaier et al.13
stabilized  closed  tibial  fractures  with  BMP-2-
coated titanium Kirschner wires. Tang et al.1
used cannulated screws with holes delivering
recombinant human BMP-2 (rhBMP-2) to the
site of FNFs in dogs. To our knowledge, there is
no comparable case in humans like ours in cur-
rent literature, though. 
The purpose of this case report was to show
that in a complicated delayed union following a
trochanteric open-wedge osteotomy after FNF
and  treatment  with  ESWT,  rhBMP-2  can  be
successfully used to induce bone formation via
computed tomography-guided injections with-
out any osteoconductor instead of autologous
bone-grafting. The patient was informed that
data from the case would be submitted for pub-
lication, and gave his consent.
Case Report
In a skiing-accident, a 50-year-old man sus-
tained a medial FNF (Pauwels III°), initially
treated by 2 hip-screws. At presentation in our
practice after 4 months, the patient was limp-
ing in pain and had leg shortening following
incomplete fracture healing (Figure 1). 
We treated the patient with 4 ESWT-sessions
using a PIEZO-Wave 6A-A 236+TQF10G4 thera-
peutic  device  (Richard  Wolf  Enterprises,
Knittlingen, Germany; 2000 impulses, 0.403mJ/
mm2, 8Hz, each). Treatment resulted in ade-
quate healing of the initial fracture-site and in
pain reduction, but with major leg shortening
inducing major problems in sports activities,
and activities of daily living (ADL). Ten months
after  the  accident/initial  surgery,  the  patient
underwent  femoral  derotational  open-wedge
osteotomy  at  an  external  hospital.  Surgery
reduced the length difference to 2.5 cm and
improved  limping;  2.5-month-postoperative
radiographs, however, revealed no sign of ossi-
fication  or  calcification  in  the  1¥4¥6  cm
osteotomy-gap  (Figure  2).  We  repeated  4
ESWT-sessions over 3 weeks which did not at
all enhance union. Four months after osteoto-
my, the open-wedge gap still showed no sign of
ossification (Figure 3). 
Unwilling to undergo another surgery, e.g.,
autologous bone-grafting, the patient agreed
on a minimally-invasive off-label alternative:
4 computed tomography-guided injections of
2  mg  of  rhBMP-2  (Inductos®)  each  were
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administered into the repair-site. The first 3
injections were given at an interval of 1 week
followed by a computed tomography (CT) con-
trol. A final injection was given 3 weeks later.
No osteoconductor was employed. On follow-
up, 6-week-post-treatment CT images showed
an  approximately  55-60%  union  (Figure  4),
while later radiographs documented a com-
plete union of the osteotomy-gap (Figure 5).
During  follow-up  examination,  ADL  and
sports  activities  were  fully  restored,  the
patient was pain-free and did not report any
side-effects. 
Discussion
We present the case history of a healthy 50-
year-old man who suffered a traumatic medial
FNF. Following surgical intervention, he devel-
oped a major leg length difference. The correc-
tion of this difference by open-wedge osteoto-
my  resulted  in  a  therapy-resistant  delayed
union at repair-site. We followed an off-label
use of a procedure based on a regional and
minimally-invasive protocol to treat the bone
defect:  The  administration  of  4  CT-guided
rhBMP-2 injections into the defect-site with-
out the use of any osteoconductor or viral vec-
tors successfully induced bone repair in the
open-wedge osteotomy-defect. Six weeks after
the last administration, rhBMP-2 had already
triggered the initial spark by initiating a 55-
60%  union  of  the  repair-site.  On  follow-up
examination,  the  patient  had  normal  radi-
ographs  showing  bone  healing  ad  integrum
and normal ADL including sports activities. 
Although the clinical potential of growth fac-
tors  to  enhance  fracture  repair  has  been
known for decades,13little is known about their
long-term  effects  and  they  have  only  been
approved for the treatment of a very limited
range of orthopaedic conditions.2,8,9 The bene-
fits of BMPs in the treatment of delayed and
non-unions are still being discussed controver-
sially.10,11 This  case  report  emphasizes  that
rhBMP-2 can be successfully used for the treat-
ment of complicated delayed unions and possi-
bly non-unions as well as an equivalent alter-
native to the gold standard of autologous bone-
grafting.  In  specific,  we  have  shown  that
rhBMP-2 can induce and enhance bone repair
even  without using  osteoconductors  which
contradicts  the  conventional  notion  of  bone
repair. Traditionally, bone healing is supposed
to require 3 components: an osteoconductor,
i.e., a scaffold over which new bone can form,
an osteoinductor, i.e., a growth factor directing
cellular  differentiation,  and  pluripotent  mes-
enchymal stem cells, i.e., the target cell for the
growth  factors.8,11 In  animal  trials,  however,
Baltzer et al.12 and Schmidmaier et al.14 as well
as Tang et al.1 have already demonstrated the
capacity of rhBMP-2 to enhance bone repair
without osteoconductors - either by using viral
vectors encoding for BMP-2 in rabbits,12 BMP-
2-coated Kirschner wires in rats13 or specific
Brief Report
Figure 1. Anteroposterior (A) and lateral (B) radiographs of the left femur 4 months after
initial surgery (2 hip-screws) show an impaction of the femoral head into the femoral neck.
Figure 2. Anteroposterior (A) and lateral (B) radiographs of the left femur 2.5 months
after derotational open-wedge osteotomy and before extracorporeal shock-wave therapy
show no sign of ossification or calcification in the osteotomy-gap.
Figure 3. Computed tomography image of
the left femur 4 months after osteotomy
and 2 weeks after the last extracorporeal
shock-wave  therapy-session  shows  an
unchanged  delayed  union  in  the  open-
wedge osteotomy-gap.[Orthopedic Reviews 2012; 4:e4] [page 19]
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delivering  devices  in  dogs1 ensuring  a  high
therapeutic concentration of BMP-2 at repair-
site. In contrast to these efforts in the animal
model, we did neither adopt the gene thera-
peutical approach by Baltzer et al.12 - which is
currently not approved of in Germany - nor the
invasive techniques by Schmidmaier et al.14 or
Tang et al.1 Instead, we used CT-guided injec-
tions  to  transport  rhBMP-2  directly  to  the
repair-site  and  administered  the  injections
repeatedly to maintain a sustainable regional
concentration  of  the  growth  factor.  This
approach seems technically safe and risk-free.
Importantly, it is additionally much less inva-
sive and painful than autologous bone-graft-
ing2 which was important to our patient, as he
did not want to undergo a third surgery within
13 months. 
With regard to negative long-term effects,
our conclusions are restricted to the (positive)
results of the 9-month-post-treatment follow-
up. Future studies should use longer follow-up
intervals, for patient safety must be our num-
ber one priority, as such a new technique is
taken from the bench to the bedside.2 Besides,
it is hard to tell whether our positive outcome
would have been the same in an older patient,
as bone healing is known to be more compli-
cated in the elderly.15,16 In spite of these limita-
tions, we believe it appropriate to consider the
regional use of rhBMP-2 as an alternative to
the last resort of autologous bone-grafting. In
view of the positive outcome of the present
case, further prospective, controlled, random-
ized  studies  in  a  larger  patient  population
seem warranted. In specific, an examination of
the  appropriate  dosage  and  administration
intervals of rhBMP-2 would be desirable. 
Delayed or non-unions are a key obstacle in
all  types  of  fractures  or  open-wedge
osteotomies.1,4 Current treatment recommenda-
tions for delayed and non-union include both
invasive procedures, such as autologous bone-
graft or osteotomy, and non-invasive techniques,
such as ESWT.2-5 The present case report shows
that growth factors, for instance, rhBMP-2, can
also be successfully used to treat complicated
delayed union following open-wedge osteotomy
in a minimally-invasive procedure without the
use of traditional osteoconductors.
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Figure 4. Computed tomography image 6 weeks after the last recombinant human bone
morphogenetic protein-2 injection shows an approximately 55-60% union of the bone
defect.
Figure 5. Nine-month-follow-up anteroposterior (A) and lateral (B) radiographs of the left
femur show a complete union of the bone defect. 